POSSIBILITY OF USING BIOCHEMICAL AND HEMATOLOGICAL PARAMETERS IN EVALUATING ADNEXAL MASSES
Abstract
Current diagnostic approach to adnexal masses (medical history, clinical examination, transvaginal sonography, tumour markers) does not provide an accurate prediction for potential malignancy. There is a possibility of using hematological and biochemical parameters (platelets count, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, platelet distribution width, level of C-reactive protein) in predicting ovarian malignancy. A retrospective study was conducted. Analysis of aforementioned parameters was performed in patients with histopathologically verified benign/malignant ovarian tumours. CRP levels, total count of granulocytes, and total count of platelets were statistically significantly higher in patients with malignant changes (p < 0.001, p = 0,001, or p = 0.023). Total lymphocytes count was statistically significantly lower in patients with malignant changes (p < 0.001). Platelet count was statistically significantly higher in patients with stage III (p = 0.011). Pl/LY ratio was statistically significantly higher in patients with stage III (p = 0.043). CRP was statistically significantly higher in stage III (p < 0.001). Lymphocyte count was statistically significantly lower in stage III (p < 0.001), and granulocyte count was statistically significantly higher in stage III (p = 0.001). Platelet count was statistically significantly higher in stage III (p = 0.001). MPV was statistically significantly lower in stage III (p = 0.031). Pl/Ly ratio was statistically significantly higher in patients with stage III (p = 0.044). Analyzed biochemical and hematological parameters are of limited utility in differentiating benign from malignant ovarian masses. Elevated levels of C-reactive protein, neutrophils and platelets suggest potentially malignant ovarian masses. Analyzed biochemical parameter (high levels of C-reactive protein, reduced lymphocyte count, increased granulocyte count, increased platelet count, increased PLR, as well as lower MPV values) may suggest advanced malignancy.
References
Amor F, Alcázar JL, Vaccaro H, León M, Iturra A. GIRADS reporting system for ultrasound evaluation of adnexal masses in clinical practice: a prospective multicenter study. Ultrasound Obstet Gynecol 2011; 38(4):450-5. [CrossRef] [PubMed]
Bakacak M, Serin S, Ercan Ö, Köstü B, Bostancı MS, Bakacak Z et al. Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to dis-tinguish malignant from benign ovarian masses. J Turk Ger Gynecol Assoc 2016;17(1):21-5. [CrossRef] [PubMed]
Bednarska K, Król E, Głowacka E, Romanowicz H, Szyłło K, Klink M et al. Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer. Medicine (Baltimore) 2018;97(12): 0180. [CrossRef] [PubMed]
Behnamfar F, Adibi A, Khadra H, Moradi M. Diagnostic accuracy of gynecology imaging reporting and data system in evaluation of adnexal lesions. J Res Med Sci 2019;24:57. [CrossRef] [PubMed]
Biggs WS, Marks ST. Diagnosis and Management of Adnexal Masses. Am Fam Physician 2016;93(8):676-81. [PubMed]
Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on pro-cesses of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172-80. [CrossRef] [PubMed]
Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005;99:447-61. [CrossRef] [PubMed]
Glanc P, Benacerraf B, Bourne T, Brown D, Coleman BG, Crum C et al. First International Consensus Report on Adnexal Masses: Management Recommendations. J Ultrasound Med 2017;36(5):849-63. [CrossRef] [PubMed]
Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumor-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011;105(1):93-103. [CrossRef] [PubMed]
Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ.The systemic inflammation-based neutrophil-lymphocyte ratio: experience in pa-tients with cancer. Crit Rev Oncol Hematol 2013; 88(1):218-30. [CrossRef] [PubMed]
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74. [CrossRef] [PubMed]
Kokanalı MK, Cavkaytrar S, Bozkurt S, Türker M, Aydın F, Doğanay M. Misdiagnosis of a Right Adnexal Mass: A Peculiar Case of Benign Appendiceal Muco-cele. J Gynecol Surg 2016;32(1):51-3. [CrossRef]
Krleža L, Zadro R, Nakić M, Sucic M, Huzjak N, Jurucevic M et al. Significance and usefulness of platelets indexes. Paediatria croatica 1999;43(2):79-85.
Migda M, Bartosz M, Migda MS, Kierszk M, Katarzyna G, Maleńczyk M. Diagnostic value of the gynecology imaging reporting and data system (GI-RADS) with the ovarian malignancy marker CA-125 in pre-operative adnexal tumor assessment. J Ovarian Res 2018;11(1):92. [CrossRef] [PubMed]
Naik R, Galaal K, Alagoda B, Katory M, Mercer-Jones M, Farrel R. Surgical training in gastrointestinal procedures within a UK gynaecological oncology sub-specialty programme. BJOG 2010;117:26-31. [CrossRef] [PubMed]
Petric A, Tubic Pavlovic A, Djordjevic I, Vucetic D, Zivadinovic R, Krtinic et al. Echinococcosis of Iliopsoas Muscle and Anaphylaxis as the Cause of Urgent Laparotomy. West Indian Med J 2014;1(3):111-3.
Petrie HT, Klassen LW, Kay HD . Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 1985; 134(1):230-4. [PubMed]
Prodromidou A, Andreakos P, Kazakos C, Vlachos DE, Perrea D, Pergialiotis V. The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-tolym-phocyte ratio in ovarian cancer. Inflamm Res 2017; 66(6):467-75. [CrossRef] [PubMed]
Sah SK, Shi X, Silin D, Li X, Shah S, Shresta K et al. CT findings and analysis for misdiagnosis of female pelvic tuberculosis. Radiol Infect Dis 2017;4(1):19-25. [CrossRef]
Sylman JL, BoyceHB, Mitrugno A, Tormoen GW, Tomas IC, Wgner TH. Temporal Examination of Pla-telet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients. 2018;SciRep(8): 6564. [CrossRef] [PubMed]
Templeton AJ, McNamara MG, Šeruga B, Vera Badillo FE, Aneja P, Ocaña A et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. JNCI 2014; 106(6):124. [CrossRef] [PubMed]
Thakur M, Thakur A, Mahajan K, Rathore S, Jindal A, Gupta G. An Interesting Case of Misdiagnosed Adnexal Mass. ASMS 2018;2(1):30-32.
Tian C, Song W, Tian X, Sun Y. Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis. Eur J Clin Invest 2018; 48(5):12917. [CrossRef] [PubMed]
Timmerman D, Van Calster B, Testa A, Savelli L, Fischerova D, Froyman W et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol 2016;214(4):424-37. [CrossRef] [PubMed]
Topcu HO, Guzel AI, Ozer I, Kokanali MK, Gokturk U, Muftuoglu KH. Comparison of Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios for Predicting Malig-nant Potential of Suspicious Ovarian Masses in Gyne-cology Practice. Asian Pac J Cancer Prev 2014;15(15): 6239-41. [CrossRef] [PubMed]
Vernooij F, Heintz AP, Coebergh JW, Massuger LF, Witteveen PO, van der Graaf Y. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol 2009;112:455-61. [CrossRef] [PubMed]
Zheng H, Tie Y, Wang X, Yang Y, Wei X, Zhao X. Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses. Medicine (Baltimore) 2019;98(7): 14577. [CrossRef] [PubMed]